Antimicrobial resistance profiles of human Brucella melitensis isolates in three different microdilution broths: the first multicentre study in Bosnia and Herzegovina.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Published by Elsevier Ltd. on behalf of International Society of Chemotherapy for Infection and Cancer Country of Publication: Netherlands NLM ID: 101622459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-7173 (Electronic) Linking ISSN: 22137165 NLM ISO Abbreviation: J Glob Antimicrob Resist Subsets: MEDLINE
    • Publication Information:
      Original Publication: Amsterdam : Published by Elsevier Ltd. on behalf of International Society of Chemotherapy for Infection and Cancer
    • Subject Terms:
      Anti-Infective Agents* ; Brucella melitensis*; Animals ; Anti-Bacterial Agents/pharmacology ; Azithromycin ; Bosnia and Herzegovina ; Drug Resistance, Bacterial ; Horses ; Humans ; Microbial Sensitivity Tests ; Sheep ; Trimethoprim, Sulfamethoxazole Drug Combination
    • Abstract:
      Objectives: Brucellosis is a ubiquitous emergent bacterial zoonotic disease causing significant human morbidity in Bosnia and Herzegovina. So far, a high rate of resistant Brucella has been found worldwide. This study prospectively analysed the rates of resistance among human Brucella melitensis strains isolated in Bosnia and Herzegovina.
      Methods: This study included 108 B. melitensis isolates from 209 patients diagnosed at five medical centres in Bosnia and Herzegovina. The resistance profiles of the B. melitensis isolates for the 13 most commonly used antimicrobials were studied in standard Brucella broth (BB) and cation-adjusted Mueller-Hinton broth (CAMHB) supplemented with 4% lysed horse blood or 5% defibrinated sheep blood.
      Results: Of the 209 patients, B. melitensis blood cultures were positive for 111 (53.1%). Among the 108 isolates investigated, 91 (84.3%) were resistant to trimethoprim-sulfamethoxazole on BB, but not on either CAMHB. Nearly all isolates (>90%) were resistant to azithromycin on BB and both CAMHBs.
      Conclusion: We observed a high rate of B. melitensis resistance to azithromycin. The high rate of resistance to trimethoprim-sulfamethoxazole that we observed was related to BB, so an alternative broth should be used, such as the enriched CAMHBs in this study, for evaluating resistance to trimethoprim-sulfamethoxazole. Whole-genome sequencing studies are needed to understand the development of antimicrobial resistance in B. melitensis strains isolated from humans.
      (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
    • Contributed Indexing:
      Keywords: Antimicrobial resistance; Antimicrobial susceptibility breakpoint determination; Bosnia and Herzegovina; Brucella melitensis; Brucellosis; Microbial sensitivity tests
    • Accession Number:
      0 (Anti-Bacterial Agents)
      0 (Anti-Infective Agents)
      8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination)
      83905-01-5 (Azithromycin)
    • Publication Date:
      Date Created: 20220219 Date Completed: 20220621 Latest Revision: 20221003
    • Publication Date:
      20240829
    • Accession Number:
      10.1016/j.jgar.2022.02.005
    • Accession Number:
      35182775